Category Archives: Tms

Historically, the RFP process has been laborious, expensive and exclusive. Shippers have aimed to work with as few carriers and brokers as possible while locking in rates on an annual basis. Over the past couple of years, market shifts and capacity constraints have illuminated the flaws in this unsustainable process.

For many years, if you talked to shippers, their whole goal was to limit the amount of carriers that had access to them. If a shipper could use one carrier for everything, they would love it. Thats just not how it works, Emerge CEO Andrew Leto said. Your average shipper in the U.S. has 15-20 carrier and broker relationships. There are 65,000 for-hire truckload carriers.

Shippers may benefit from limiting the number of partners they work with in a loose market, but this exclusionary approach has become a serious and seriously expensive problem as capacity has tightened and rates have climbed to record highs.

You have to start looking at your supply chain and knowing where your gaps are, Leto said. One of the biggest problems in this industry is the capacity matching.

Most shippers are still relying on spreadsheets and emails to deal with both spot and contract bids. At a time when shippers are being forced to run more spot bids than ever, this process can be a real liability, as it tends to be inefficient and opaque.

You have to run a bid, get new carriers, manually award the bid and then manually change the route guide in TMS, Leto said. You cant be agile doing that. Emerge will automatically change route guides in your TMS, making you much quicker and faster.

In order to thrive in the current market, Leto encourages shippers to ditch their old solutions in favor of a multifaceted, tech-savvy approach. Shippers should be taking advantage of cutting-edge visibility solutions, modern benchmarking options and a good RFP platform that works with their TMS.

The best RFP platforms, like the one offered by Emerge, not only play well with a shippers TMS, but also bring their freight out into the light, giving a wider network of carriers and brokers access to the shippers freight. This helps combat the market tightness and sky-high rates shippers have been grappling with.

When these easy-to-use RFP platforms are coupled with benchmarking tools, like FreightWaves SONAR, shippers gain even more control over their shipments. With strong benchmarking and predictive freight rates, shippers can decide whether a shorter or longer RFP is right for them at any given moment, ensuring they do not get locked into subpar rates over the long term.

Click here to learn more about how Emerge is reinventing freight procurement.

Read the original:

Old-school RFP processes are keeping shippers in the past - FreightWaves

INTERVIEW: Phil Tufnell and Jonathan Agnew will soon embark on a 20-day tour to celebrate the iconic Test Match Special programme, and England's Ashes debacle will be up for discussion

Video Unavailable

Play now

Sue Barker, Matt Dawson & Phil Tufnell to leave Question of Sport

Former England Test spinner Phil Tufnell has called for changes to be made to the county cricket calendar following the latest Ashes debacle down under.

In April and May, Tufnell, 55, will be joined by colleague Jonathan Agnew on a 20-date live Test Match Special [TMS] tour, with the iconic duo set to regale audiences with the highlights of their careers, both on the field and in the commentary box.

And in an interview with The Mirror , 'The Cat' admitted "the England shambles down in Australia might get a mention."

Tufnell himself played in 12 Ashes Tests during an international career that spanned 11 years, with one of his finest hours coming in 1997 at The Oval when he took match figures of 11-93 to secure a dramatic home victory.

Image:

However, by that point, Australia had already retained the urn and the Middlesex man was able to relate to the current crop of players during their harrowing 4-0 series defeat this winter.

"I covered some of it [The Ashes] some of it during the winter and must admit it was a tough watch at 4am in the morning," he said.

"Of course the preparation, the covid bubbles, the isolation and all that stuff - it has been very, very tough for the team. But at the end of the day we didn't perform and it's as simple as that.

"I've been on a few Ashes tours and when you get a good walloping down under everyone comes back and wrings their hands - and says we got to change this and look at structures and so have you."

Tufnell stopped short of calling for drastic change, but did identify a key area where English cricket can help its red-ball side.

"I think they have now decided to put three or four County Championship games in the middle of the summer. We need that.

"We've got to play on better pitches and we've got to play as much in middle of summer as we can.

"We can't be playing red ball at the beginning of April when snow is on the ground and you got 10 jumpers on - and everyone is getting bowled out for 100 on green decks. And we can't also be playing in October when there are leaves on the the ground.

"We're a fantastic white-ball cricketing side now but the red ball just needs a bit of TLC and looking after at the moment. And people above my pay grade are looking into how we structure it.

Image:

"Everyone loves Test cricket and wants to play it. It's the pinnacle, it just needs tinkering, not massive overhauls."

In the meantime, Tufnell will focus on his return to the live stage, albeit in a different capacity to when he was starring in pantomime and hosting A Question of Sport.

"I'm really looking forward to it [the tour] and can't believe they haven't done one beforehand.

"I've done working in the theatres and you get a great feedback from an audience. Sometimes on television you can't digress, but you can wander around a bit more on a stage or on the radio. I'm sure we'll wander down a few paths and end up in a few cul-de-sacs along the way so who knows where we're gonna end up?

"It's just going to be like a normal TMS show with a few other things thrown in along the way."

Phil Tufnell and Jonathan Agnew will be on the road with The Test Match Special Tour throughout April and May 2022. Tickets available from http://www.fane.co.uk/tms.

Read More

Read More

Link:

Phil Tufnell identifies key change to be made if England are to recover from Ashes mess - The Mirror

You sit in a comfortable chair, wearing earplugs. A clinician puts a magnetic coil on your scalp, toward the front

You sit in a comfortable chair, wearing earplugs. A clinician puts a magnetic coil on your scalp, toward the front of your head. You feel a tapping on your forehead and hear clicking sounds as the machine turns on and the transcranial magnetic stimulation, or TMS, begins.

By this point, the TMS expert physician has already determined the minimum amount of power needed to stimulate your brain cells, this will meet your individual threshold and can cause your thumb muscles to twitch. Now, the TMS technician administers the actual treatment. Your scalp may tingle as the magnetic pulses pass through to your brain.

Youre awake and alert for the half-hour or so that the procedure takes. Once treatment is done and the coil comes off your head, you leave and go about your normal daily routine.

You repeat the TMS treatment five days a week, Monday through Friday, for the next six weeks or so. The goal: That persistent depression symptoms will improve or disappear entirely. You may experience some change in symptoms after a week or two, but a typical course takes over a month to bring remission.

Not everyone with depression is a candidate for TMS. To qualify for insurance coverage in the U.S., you must have a diagnosis of major depressive disorder and already tried one or more antidepressant medications but experienced inadequate or no symptom relief.

Not everyone responds to TMS, either. But for those who do, the noninvasive treatment helps them feel better and once again be able to enjoy things and function like they did before their depression began.

[SEE: 11 Tips to Support Someone Struggling with Mental Health.]

What TMS Is

TMS is a noninvasive procedure using magnetic fields to stimulate nerve cells, or neurons, in the brain. Treatment is given through repetitive magnetic pulses, known as repetitive TMS, rTMS, or TMS therapy.

In a standard TMS session, clinicians place an electromagnetic coil on your scalp near your forehead. This coil delivers a series of magnetic pulses to stimulate neurons in the cortex brain areas involved in regulating emotions. TMS is believed to work by activating brain regions and networks that are malfunctioning when a person has persistent depression.

While its difficult to give a precise number of individual patients who receive TMS yearly, it is estimated that more than 20 million treatments have been given in the U.S. since it was approved by the Food and Drug Administration in 2008, says Dr. Linda Carpenter, a psychiatrist at Butler Hospital and a research professor in the department of psychiatry and human behavior at Brown University. Carpenter directs the Butler Hospital TMS Clinic and Neuromodulation Research Facility in Providence, Rhode Island.

Patients that qualify for TMS are those who have failed to get better with standard antidepressant medication, Carpenter says. Thats probably a third of all patients that get treated for depression.

Its important not to confuse TMS with the electricity-based treatment called electroconvulsive therapy, or ECT, although both are used for treatment-resistant depression. ECT uses electrical currents, rather than the magnetic fields that TMS uses. ECT causes a brief, controlled seizure that affects neurons and brain chemicals as its treatment goal. By contrast, TMS therapy activates targeted brain areas, and patients are awake and aware throughout.

Unlike some other forms of brain stimulation, TMS does not require implanted electrodes or surgery. Nor does TMS require anesthesia, unlike ECT.

[See: 7 Signs of Depression in Men.]

Who It Treats

Devices capable of delivering transcranial magnetic stimulation to the human brain were first developed in 1985.

In 2008, the FDA approved TMS for adults with depression thats resistant to standard treatments. Specifically, its currently approved for whats called primary major depressive disorder without psychotic symptoms, Carpenter says. Psychotic symptoms relate to being out of touch with reality, such as hallucinations or delusions. The depressive syndrome for which TMS is approved is characterized by a certain number of symptoms that persist for weeks: depressed or low mood, loss of ability to experience pleasure and problems with sleeping, appetite, interests, concentration and motivation. Sometimes anxiety is also a symptom.

TMS represents a significant therapeutic option for people in need. It plays a really important role in what we refer to as treatment-resistant depression,' says Dr. Alexander McGirr, principal investigator for the McGirr Lab, part of the Hotchkiss Brain Institute of the University of Calgary in Alberta, Canada.

In Canada, our guidelines advocate that after a single failed antidepressant, you should be considering TMS, McGirr says. Because it has a different mechanism of action, youre more likely to get benefit from it than you would be from switching to a different medication.

In 2018, the FDA approved TMS to treat obsessive-compulsive disorder, or OCD. In 2020, TMS was approved as a smoking cessation therapy.

Researchers have investigated rTMS for a variety of brain-based disorders, such as relapsing multiple sclerosis and Parkinsons disease. However, most of these are not FDA-approved indications.

Patient Experience

The Butler Hospital Clinic treats about 100 new patients a year, along with many returning patients, Carpenter says. Sometimes the patients will get better and then come back again a couple years later, or at some point in the future, to get a repeat course of treatment if their depression comes back, she says.

Carpenter describes how TMS works: Magnetic energy passes through your scalp and your skull tissues, she says. Its pulsed from a little device called a coil that sits on your head. When magnetic pulses reach the brain tissue called the cortex, the outer layer of the brain, it induces current activation. Your neurons conduct electricity and this induces electrical current in the neurons located under the coil. These neurons produce electricity and use it to send signals to neurons in other areas of the brain, so there is communication through brain networks.

According to patient feedback, Carpenter says, The first day of TMS might feel like theres a woodpecker pecking on your head. Theres percussion or tapping sensation when the pulses are delivered to the patients head. Sometimes theres a little bit of a twitching in the muscles around the forehead, and scalp around the coil, because TMS can activate nerves to some of those muscles we use to raise our eyebrows or make facial expressions.

Most patients become accustomed to TMS after a couple sessions. The sensation is diminished and they dont feel that much, Carpenter says. Sometimes it feels sort of soothing and people get drowsy during the stimulation; they get used to it. Your brains awareness of the sensation tunes down and accommodates to it, so it doesnt really feel like much after youve had a few sessions.

TMS Effects

TMS effects can be measured both in the area of the brain directly beneath the coil, called the prefrontal cortex, as well as through connections or relationships with other areas of the brain that are deeper and further back, Carpenter explains.

It doesnt take long for patients to start seeing results. During the first week, they might have a little more energy than before, Carpenter says. After a week or two of daily TMS, patients start to notice: Gee, Im more interested in things, I have more energy and Im concentrating better.' For the Butler clinic, Carpenter notes, We usually see gradually accumulating symptom improvement over the weeks.

Of his TMS patients, McGirr says, When it works, its really quite remarkable. About 25% experience an extremely rapid response. Sometimes theyll use metaphors: Its like a light went on and they see the light again, he says. And they feel much better.

About half of patients have a gradual, progressive improvement, McGirr says. They describe it as a slow improvement and they didnt really notice it much, at first, he says. Then they started to notice things at the two-to-four week mark. Changes continue, with other people in patients lives commenting on the difference.

However, some patients dont have improvement even after daily TMS treatment for up to six weeks. Unfortunately, there are those people who do not benefit from this treatment and that can be a little bit frustrating, because it is a fairly demanding treatment, McGirr says.

Types of TMS

Various TMS devices deliver magnetic brain stimulation using different treatment protocols. These include:

Repetitive transcranial magnetic stimulation. As described above, rTMS is the established version. Typically, it involves high-frequency stimulation to the brains prefrontal cortex.

Intermittent theta burst stimulation. Also called iTBS, this newer form of rTMS is also FDA-approved for stimulating the cortex in once-daily sessions. A course of therapy requires the same number of weeks, but each session is shorter because magnetic pulses are delivered very quickly.

[READ: 7 Tips for Living With Depression.]

Side Effects

During TMS treatment, while attached to the coil, patients may experience side effects including:

Headache.

Facial muscle tingling or twitching.

Scalp discomfort or irritation.

Lightheadedness or dizziness.

Hearing loss (preventable by proper earplug use).

Rare but serious side effects may include:

Seizures.

Mania in people with bipolar disorder.

Although the risk of seizures with TMS treatment is less than 1% overall, it does exist, according to an evidence review published in December 2020. Proper screening to rule out TMS treatment for individuals at increased seizure risk is an important step in prevention, according to an April 2020 National Institute of Mental Health expert lecture on TMS risks and safety.

Adding TMS to the Treatment Arsenal

Medication and psychotherapy, or talk therapy, are first-line treatments for depression. However, access to talk therapy can be difficult with only a limited number of sessions covered by insurance. Antidepressant medications work for many people, but they may cause burdensome side effects in others.

For example, the most frequently prescribed class of antidepressants is the selective serotonin reuptake inhibitors. Agitation and anxiety, sexual problems like low libido, dizziness, headaches, nausea, diarrhea, insomnia and tremor can all be SSRI side effects.

Even among those who originally respond to antidepressant medications, the effectiveness can wane over time. Alternatives or adjuncts may be needed to fill treatment gaps.

The advantage of TMS is that its a fundamentally different way of treating the depression, whereas a lot of our medications have common mechanisms of action, McGirr says. So, we know that when switching (from one depression medication) to the next, you get vanishingly smaller return for your investment with each step you go.

By contrast, moving to TMS may make a notable impact. Switching to something that works entirely differently so actually trying to drive plasticity in the parts of the brain related to depression we can try to get at the neurocircuitry thats changed with depression and try to restore it, McGirr says. In other words: Were trying to make the brain work the way it did before depression.

Oftentimes, patients treated with TMS continue to take their antidepressant medications. We usually recommend that people stay on their medications because they have gotten some effect, and the medications themselves have a variety of effects on the brain that could potentially be healing of the brain, McGirr says.

Evaluation for Treatment

Patients considering TMS typically undergo a physical and psychiatric evaluation to determine if the treatment is safe and appropriate for them. Clinicians will also ask patients other medical conditions, pregnancy, medications or supplements they take, and alcohol and substance use among other information.

Reasons that patients may not be recommended to receive TMS include:

Having implanted devices such as heart stents, aneurysm clips or coils, implanted stimulators or electrical medical devices like a pacemaker or a cardioverter-defibrillator, cochlear hearing implants, bullet fragments or other nonremovable metal implants inside the body within a few feet of the head. Dental metal is not a problem.

Seizure history or epilepsy.

Brain illness or significant history of brain injury, such as a stroke, brain tumor or traumatic brain injury.

Data: Does TMS Help?

A growing body of evidence finds TMS effective for patients with major depressive disorder that hasnt responded well to standard treatments.

A randomized clinical trial with data supporting TMS treatment was published in 2007, showing about 24% of depressed patients responded to the treatment. A subsequent trial, funded by the NIMH, was published in May 2010. During the first study phase, about 15% of participants achieved remission a symptom-free period in their depression. During the second study phase, nearly 30% experienced remission.

A meta-analysis of 81 studies encompassing nearly 4,250 patients treated with various types of TMS, published in February 2017 in JAMA Psychiatry, found all types more effective, and at least as tolerable, as sham (placebo) TMS treatment for major depressive episodes.

The Three-D study, published in April 2018 in The Lancet, which compared rTMS and iTBS, found them equally safe, tolerable and effective in treating patients with major depressive disorders.

A meta-analysis of 10 studies encompassing nearly 700 patients, published in May 2021 in the journal Translational Psychiatry, found a similar, positive effect rates for both rTMS and theta burst stimulation compared to sham TMS treatment for major depressive disorder.

A small study of a new, intensive form of TMS called Stanford neuromodulation therapy, published in October 2021 in the American Journal of Psychiatry, found rapid improvement in nearly 80% of the 29 participants, all with severe, treatment-resistant depression. This form of TMS, which involves 10 TMS sessions per day, will be evaluated in large clinical trials to determine if it is suitable for standard TMS practice.

A study of 700 U.S. military veterans, appearing in the January 2022 issue of the Journal of Affective Disorders, found TMS was effective in treating veterans with major depressive disorder, including participants with symptoms of posttraumatic stress disorder.

Its unclear whether TMS works for different forms of depression. For instance, a randomized clinical trial of 37 patients with bipolar depression, led by McGirr and published in March 2021 in JAMA Network Open, did not find theta burst stimulation more effective than sham TMS. Bipolar depression is characterized by periods of mania as well as depression, unlike the unipolar depression for which TMS treatment is approved.

Seeking TMS

If youre looking into TMS for depression, choose the treatment facility carefully and ask questions. The main thing that patients want to look for is a practice with doctors and clinic staff that are providing evidence-based care, Carpenter says.

There are a lot of different brain regions and a lot of different stimulation protocols that could be used in TMS care, Carpenter says. But you want to find a doctor and a clinic that will deliver a published, scientifically sound stimulation protocol. And its important that patients look for a clinic where TMS physicians are prescribing the stimulation and day-to-day monitoring is done by TMS clinicians who are skilled and trained.

Check your insurance coverage. For a regular course of TMS therapy to treat depression, all insurance companies now and federal payers Medicare/Medicaid all cover a course of TMS to treat depression, Carpenter says. Many policies have different criteria and they require that you have failed a certain number of antidepressant medication trials. Policies describing coverage criteria for TMS practice have changed over time as the evidence base has evolved. At this point, TMS coverage is fairly good for appropriate candidates, but not every person who could benefit lives near a TMS clinical practice.

Its not too soon to consider TMS if youre suffering from depression without relief, McGirr says. This is something that should be on the table as soon as any first-line intervention any medication trials have failed or any psychotherapy has failed and somebody is having continuing depression and they have not responded to some of our best treatments, he says. (TMS) is something that should be in the discussion early.

More from U.S. News

What to Know About Anxiety Medications

Questions Doctors Wish Their Patients Would Ask

Tips to Manage Stress at Work

What Is TMS Treatment for Depression? originally appeared on usnews.com

See original here:

What Is TMS Treatment for Depression? - WTOP

Treatments for clinical depression and anxiety range from medication to psychotherapy, but there is a new, experimental treatment in consideration by researchers as of late: magic mushrooms.

A study published November 4, 2020, by Johns Hopkins Bayview Medical Center researchers from the Center for Psychedelic and Consciousness Research in Baltimore, Maryland found that psilocybin (more commonly known as magic mushrooms), when given in conjunction with psychotherapy, decreased depressive symptoms in participants.

This study, conducted in 2017 and 2019 at Johns Hopkins, consisted of 24 participants who had long-term histories of depression. They received doses of psilocybin and followed up with researchers one week and four weeks after receiving the treatment. Most participants showed improvement and half ended up achieving remission essentially depression-free or at least symptomless when followed up with four weeks after receiving the experimental treatment.

Researchers at Johns Hopkins have also conducted studies over the years that have found psilocybin decreases cancer-related anxiety in cancer patients and may lead to helping smokers quit and treatments for alcohol abuse.

But Johns Hopkins is not the only place where psilocybin research is being centered when it comes to treating various psychological disorders.

Compass Pathways, which is an organization that is dedicated to accelerating patient access to evidence-based innovation in mental health, ran a study this year with over 200 participants that also showed marked improvement in the symptoms of people receiving psilocybin treatment as opposed to a control group that received a placebo.

Some states are legalizing psilocybin for therapeutic use. In 2020, following the release of the results from the Hopkins study, the state of Oregon legalized it and laid out plans for its therapeutic use. On a federal level, though, psilocybin continues to be considered a Schedule I drug, meaning it is a drug with no currently accepted medical use and a high potential for abuse, according to the United States Drug Enforcement Administration. Other examples of these include marijuana, peyote, and heroin.

Furthermore, these treatments are new and still in the process of being researched, in spite of their success in studies like the one at Hopkins. They are not yet readily accessible, and experts warn about potential adverse effects and lack of in-depth research, saying not to try psilocybin as a means of treating depression just yet.

In a blog post, Psych Atlantas medical director Dr. Michael Banov pointed out the risks and unknowns associated with psilocybin as a treatment for mental health problems. He mentions many reasons, including the fact that the substance is currently illegal you could not receive a prescription for it and the complexity of using treatments we do not yet know much about the side effects of or whether there are interactions with other medications, etc.

Its too risky now, Dr. Banov writes. We dont know if it could make certain patients mental health worse or be dangerous with some medications, medical conditions, or supplements you are taking. If youre looking for treatment alternatives, stick with those with a longer track record and are legal, such as medication combination therapies, off-label medicines that have been shown to be helpful, Transcranial Magnetic Stimulation (TMS), ketamine or Spravato, or natural supplements.

Symptoms of clinical depression or major depressive disorder (MDD) include persistent feelings of sadness or emptiness, feelings of worthlessness or pessimism, fatigue, trouble concentrating, loss of interest, and crankiness, among many other behavioral and emotional responses.

Continue reading here:

Psilocybin Could Be Next Frontier for Depression and Anxiety Treatment - Georgia Voice

Enlarge photo.

Tonganoxie school district officials are continuing to look into the practicality of installing artificial turf at Beatty Field. USD 464 board members met with Superintendent Loren Feldkamp and Assistant Superintendent Tonya Phillips and school administrators during a special meeting Monday in the Tonganoxie High School library.After a lengthy discussion about the merits of turf and how it should be handled as a priority with improving district facilities, the board agreed to look at the possibility of fundraising and the forming of a committee.

Tonganoxie USD 464 will be requiring masks in campus buildings for the next two weeks.

Per information the district released Thursday evening, the mask requirement begins Friday and will continue for two weeks after district officials reviewed current COVID-19 numbers.

The district had 30 positive cases 26 students and four adults a few days after classes resumed after winter break. There also were 47 students in quarantine and one adult in quarantine as of Thursday.

Student cases by school are 11 at Tonganoxie High School, six at Tonganoxie Middle School and nine at Tonganoxie Elementary School. The adult cases are two at TES and two at TMS. As for quarantined students, 29 are from TES, three from TMS and 15 from THS. Theres also one adult at TES quarantining.

The number of cases more than doubled since Tuesday when there were seven positive student cases at TES and six at TMS. There were no positive cases at THS, though students had a remote learning day, so Wednesday marked the first day when students returned to in-person instruction.

Read more:

Tonganoxie USD 464 moves back to required masks for 2 weeks | TonganoxieMirror.com - The Mirror

A research team in Sweden found TMS could be an effective option for treatment of alcohol addiction.

The Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linkping University, Sweden, has released a study in which deep, repetitive transcranial magnetic stimulation (TMS) showed promise for the treatment of alcohol addiction. The findings were published in the December 5 online edition of Biological Psychiatry.

The team noted, Alcohol addiction is associated with a high disease burden, and treatment options are limited. In a proof-of-concept study, we used deep repetitive transcranial magnetic stimulation (dTMS) to target circuitry associated with the pathophysiology of alcohol addiction. We evaluated clinical outcomes and explored associated neural signatures using fMRI.

In the trial study, the researchers enrolled and randomly assigned 51 treatment-seeking adults with moderate to severe alcohol dependence to receive an active or placebo treatment. Beforehand, these individuals completed craving induction, which included holding and smelling but not consuming an alcoholic beverage, the team reported.

The randomized, double-blind, placebo-controlled trial offered study participants TMS targeting the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC) for three weeks. The results shows that the treatment significantly reduced heavy drinking days compared to a group of participants who received a placebo treatment. The team reported TMS is safe and effective in decreasing symptoms of alcohol addiction and brain reactivityThe active treatment group also reported significantly less alcohol craving and showed less functional connectivity on MRI in areas of the brain that can trigger craving and relapse.

Clinicians should keep their eyes open in the wake of this phase 2 trial, said co-corresponding author Markus Heilig, MD, PhD, professor of psychiatry and director at the Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Linkping University, Sweden. He added, If and when this replicates in the equivalent of a phase 3 study, we will actually have a completely novel treatment available for this difficult to treat and very impactful disease.

Heilig explained that before stimulating the brain, you want to make it as malleable as possible; and brain networks tend to be more malleable when they are active. This is why the holding and smelling of the alcoholic drink was key before proceeding with TMS or the placebo.

During the three-week treatment, active or sham stimulations were delivered in five 30-minute sessions per week, the study notes. During the sessions, all participants wore a helmet with a deep TMS coil produced by BrainsWay.

In the active stimulation group, each session included 100 trains of 30 pulses at 10Hz (3 seconds) with 15-second intervals, for a total of 3000 pulses. The sham stimulation produced the same acoustic artifact and generated skin sensations mimicking those of the active stimulation, but it did not involve a magnetic field. Participants, operators, and raters were blinded to the type of coil used, according to the research team.

Five participants had to be eliminated from treatment due to relapsing during the three-week trial. Two-thirds of participants were males and Heilig noted that the gender makeup reflects what a real treatment-seeking group looks like.

Repetitive transcranial magnetic stimulation in alcohol dependence: A randomized, double-blind, sham-controlled proof-of-concept trial targeting medial prefrontal and anterior cingulate cortex

Transcranial Magnetic Stimulation Shows Promise for Alcohol Addiction

Continue reading here:

TMS Therapy is 'Promising' for Alcohol Treatment - Legal Reader

The "Global Transportation Management Systems (TMS) Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

This transportation management systems (TMS) market is poised to grow by $2.95 Billion during 2021-2025, progressing at a CAGR of 11.11%

This study identifies the shift from the CAPEX model to the OPEX model as one of the prime reasons driving the transportation management systems (TMS) market growth during the next few years. The market is driven by the increase in the number of smart connected devices and the increasing need for efficient operations.

The report the transportation management systems (TMS) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The transportation management systems (TMS) market analysis includes the solution segment and geographic landscape.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading transportation management systems (TMS) market vendors that include C.H. Robinson Worldwide Inc., Continental Traffic Service Inc., E2open LLC, Koch Industries Inc., Manhattan Associates Inc., Oracle Corp., Panasonic Corp., SAP SE, The Descartes Systems Group Inc., and Trimble Inc.

Also, the transportation management systems (TMS) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Solution

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/r/63ay6z

View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005184/en/

View post:

Global Transportation Management Systems (TMS) Market 2021-2025 - Shift from the CAPEX Model to the OPEX - Benzinga

Advance Market Analytics published a new research publication on 3PL Software Market Insights, to 2026 with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the 3PL Software market was mainly driven by the increasing R&D spending across the world.

Some of the key players profiled in the study are:

ShipBob (United States),HighJump (United States),Datex Corporation (United States),Flowspace, Inc. (United States),ChannelApe (United States),Manhattan Associates (Georgia),VeraCore Software Solutions Inc. (United States),3PL Warehouse Manager (United States),Logistically TMS (United States),Camelot 3PL Software (United States),

Get Free Exclusive PDF Sample Copy of This Research @ https://www.advancemarketanalytics.com/sample-report/114363-global-3pl-software-market

Scope of the Report of 3PL Software3PL software is known as third-party logistics software. It is an integrated technology platform to address all the critical components of several client 3PL operations. This software is used to manage to outsource supply chain activities such as transportation and warehousing. Owing to the growing demand of this software by third-party logistics providers to plan, schedule and monitor supply chain operations.The titled segments and sub-section of the market are illuminated below:

by Application (Transportation, Warehouse, Others), Platforms (Windows, IOS, Linux, Android), Business Size (SMEs, Large Enterprises), Deployment (Cloud-Based, On-Premise)Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.Market Trends:Implementation of Artificial Intelligence in Third-Party Logistics Platforms

Opportunities:Development in E-Commerce Industry will expect to Create Huge Opportunities for this Market

Market Drivers:Development in E-Commerce Industry will expect to Create Huge Opportunities for this Market

Challenges:Requirement of Skilled Professionals to Operate this Software

Have Any Questions Regarding Global 3PL Software Market Report, Ask Our [emailprotected] https://www.advancemarketanalytics.com/enquiry-before-buy/114363-global-3pl-software-market

Strategic Points Covered in Table of Content of Global 3PL Software Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the 3PL Software market

Chapter 2: Exclusive Summary the basic information of the 3PL Software Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the 3PL Software

Chapter 4: Presenting the 3PL Software Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020

Chapter 6: Evaluating the leading manufacturers of the 3PL Software market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2026)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

finally, 3PL Software Market is a valuable source of guidance for individuals and companies.Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/114363-global-3pl-software-marketContact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

Continued here:

3PL Software Market to Eyewitness Massive Growth by 2026 | Datex, VeraCore Software Solutions, Logistically TMS Industrial IT - Industrial IT

The Japanese manga series, Dr. Stone has been renewed for Season 3 just after the release of Season 2, which was aired from January to March 2021.

Recently, in Jump Festa 22, the Dr. Stone production team has released a teaser and announced that a special episode, titled RYUSUI will be released in summer 2022. The trailer also reveals that the wait for the third season will be a bit longer. Dr. Stone Season 3 is to be premiered in 2023.

Ryusui Nanami is a new addition to the Senku's Kingdom of Science. Ryusui will be voiced by Ryota Suzuki for the anime, and the special will be produced by TMS Entertainment once more and will feature a bunch of returning cast.

The manga series is written by Riichiro Inagaki and illustrated by the South Korean artist Boichi. Dr. Stone will see the adaptation of the Age of Exploration arc from the original Dr. Stone manga series. According to Comic Book, the plot will revolve around Perseus being built by the gang, making "Thousand Sunny" jealous. Hopefully, Ryusui will also play a vital role in Dr. Stone Season 3.

Dr. Stone Season 2 is focused on the story of the "Stone Wars" arc from the manga series that was officially titled Dr. Stone: Stone Wars. The story takes place in April 5738 AD (over 3,700 years later), when humans turn into stones after a mysterious incident. The story mostly focuses on a 15-year-old genius boy SenkuIshigami, who resurrects thousands of years after.

He finds himself in a world where all traces of human civilization have been eroded by time. Senku sets up a base camp and begins to study the petrified humans in order to determine the cause of the event, as well as a cure.

He takes six months to study and gives life to his friend Taiju Oki with nitric acid. And they work together to save the rest of humanity.

Dr. Stone Season 3 will be premiered in 2023. We will keep updating the news as soon as we get anything new on it. Till then stay tuned!

Also Read: Dr. Stone Chapter 224: The rocket could face some troubles during takeoff

See the rest here:

Ryusui to be the central character of Dr. Stone special episode but will he appear in Season 3? - Devdiscourse

SAN MATEO, California, Dec. 14, 2021 /PRNewswire/ -- Turvo, provider of the world's leading collaboration application designed for the supply chain, announced today that its collaborative TMS now features a routing guide that automates workflow and carrier assignment, creating a seamless end-to-end Turvo platform experience.

With the industry's most advanced routing guide now powering Turvo's TMS, shipments are automatically offered out to various carriers, carrier groups, and/or bid boards based on rules and requirements set up by an admin user. Built by Turvo's award winning engineers, Turvo continues to offer industry-leading TMS solutions, in the most collaborative and connected ecosystem available in the supply chain space.

"Turvo's automated routing guide rounds out a bundle of powerful features that give us a competitive edge," said Steve Lyons, President, Vine Line Logistics, LLC. "We're now able to secure capacity for our customers more efficiently than ever before, freeing up our team to be more responsive."

Turvo's collaborative logistics platform unifies existing workflows, giving customers access to scaled growth through computing, rather than personnel. The routing guide further automates existing Turvo Marketplace functionalities, while enhancing its network capabilities.

Turvo's TMS gives freight brokers, third-party logistics providers (3PLs), and shippers a place to plan, execute, settle, and automate all their supply chain operations, on one platform, with a network approach.

These critical capabilities include:

"Our TMS features the most powerful and comprehensive applications available in logistics," said Scott Lang, Chairman and CEO, Turvo. "With the industry's most advanced routing guide, Turvo takes automation and collaboration to a new level, giving companies the marketplace capabilities needed to capture new business in a dynamic and challenging market."

About Turvo

Turvo provides the world's leading collaboration application designed specifically for the supply chain. Turvo connects people and organizations allowing shippers, logistics providers, and carriers to unite their supply chains, deliver outstanding customer experiences, collaborate in real-time, and accelerate growth. The technology unifies all systems, internal and external, providing one end-to-end solution to execute all operations and analytics while eliminating redundant manual tasks and automating business processes. Turvo customers include some of the world's largest, Fortune 500 logistics service providers, shippers and freight brokers. Turvo is based in the San Francisco Bay Area with offices in Dallas, Texas, and Hyderabad, India. (www.turvo.com)

For media inquiries, please contact Samantha Foley at 214-263-3547 or[emailprotected].

SOURCE Turvo Inc

Read more:

Turvo's Routing Guide Supercharges its Industry Leading Collaborative TMS - PRNewswire